See more : Bullpen Parlay Acquisition Company (BPAC) Income Statement Analysis – Financial Results
Complete financial analysis of Clínica Las Condes S.A. (LAS-CONDES.SN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Clínica Las Condes S.A., a leading company in the industry within the sector.
- Telstra Group Limited (TLS.AX) Income Statement Analysis – Financial Results
- Orion Energy Systems, Inc. (OESX) Income Statement Analysis – Financial Results
- Computer Programs and Systems, Inc. (CPSI) Income Statement Analysis – Financial Results
- Patron Exim Limited (PATRON.BO) Income Statement Analysis – Financial Results
- Jiangsu Akcome Science and Technology Co., Ltd. (002610.SZ) Income Statement Analysis – Financial Results
Clínica Las Condes S.A. (LAS-CONDES.SN)
Website: https://www.clinicalascondes.cl
About Clínica Las Condes S.A.
Clínica Las Condes S.A. operates clinics in Chile. The company provides services in the areas of anesthesiology, adult and infant bronchopulmonary, cardiology, adult and child surgery, plastic and reconstructive surgery, dermatology, gastroenterology, obstetrics-gynecology, maxillofacial, physical medicine and rehabilitation, internal medicine, neurosurgery, adult and child neurology, nutrition, odontology, ophthalmology, otorhinolaryngology, pediatrics, child and adolescent psychiatry, adult psychiatry, traumatology and orthopedics, and urology. Clínica Las Condes S.A. was founded in 1978 and is based in Las Condes, Chile. Clínica Las Condes S.A. is a subsidiary of Lucec Tres, S.A.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 202.26B | 259.99B | 276.85B | 212.27B | 226.19B |
| Cost of Revenue | 143.12B | 178.49B | 203.10B | 175.66B | 178.25B |
| Gross Profit | 59.15B | 81.51B | 73.75B | 36.61B | 47.95B |
| Gross Profit Ratio | 29.24% | 31.35% | 26.64% | 17.25% | 21.20% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 17.65B | 26.20B | 14.48B | 12.47B | 24.76B |
| Selling & Marketing | 788.72M | 500.98M | 555.65M | 644.93M | 908.59M |
| SG&A | 18.44B | 26.70B | 15.04B | 13.12B | 25.67B |
| Other Expenses | 40.70B | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 59.15B | 54.19B | 31.88B | 30.01B | 35.66B |
| Cost & Expenses | 202.26B | 232.68B | 234.98B | 205.66B | 213.91B |
| Interest Income | 384.85M | 1.04B | 249.52M | 538.01M | 135.57M |
| Interest Expense | 10.57B | 9.28B | 7.72B | 7.12B | 8.01B |
| Depreciation & Amortization | 3.34B | 2.53B | 1.92B | 1.61B | 13.12B |
| EBITDA | 1.44B | 8.49B | 31.55B | 2.71B | 33.71B |
| EBITDA Ratio | 0.71% | 3.26% | 11.39% | 1.27% | 14.90% |
| Operating Income | 7.66B | 5.96B | 29.62B | 1.10B | 20.59B |
| Operating Income Ratio | 3.79% | 2.29% | 10.70% | 0.52% | 9.10% |
| Total Other Income/Expenses | -20.13B | -9.28B | -23.00B | -11.84B | -12.84B |
| Income Before Tax | -12.47B | -3.32B | 21.90B | -10.75B | 5.02B |
| Income Before Tax Ratio | -6.17% | -1.28% | 7.91% | -5.06% | 2.22% |
| Income Tax Expense | -9.07B | -7.37B | 3.48B | -4.93B | 367.94M |
| Net Income | -3.40B | 4.05B | 18.42B | -5.28B | 5.22B |
| Net Income Ratio | -1.68% | 1.56% | 6.65% | -2.49% | 2.31% |
| EPS | -303.06 | 483.00 | 2.20K | -630.36 | 623.16 |
| EPS Diluted | -303.06 | 483.00 | 2.20K | -630.36 | 623.16 |
| Weighted Avg Shares Out | 11.22M | 8.38M | 8.38M | 8.38M | 8.38M |
| Weighted Avg Shares Out (Dil) | 11.22M | 8.38M | 8.38M | 8.38M | 8.38M |
Source: https://incomestatements.info
Category: Stock Reports